Frazier Life Sciences Management L.P. bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 69,406 shares of the biopharmaceutical company’s stock, valued at approximately $16,059,000. Frazier Life Sciences […]
Bain Capital Life Sciences Investors LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 324,619 shares of the biopharmaceutical company’s stock, valued at approximately $75,110,000. Madrigal Pharmaceuticals comprises approximately […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]
Rhenman & Partners Asset Management AB bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,500 shares of the biopharmaceutical company’s stock, valued at approximately $5,206,000. Several other hedge funds […]